Wesley Mizutani

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVE To develop and validate multiattribute measures for patients with rheumatoid arthritis (RA) to report health states and estimate preference weights. METHODS Survey materials were mailed to 748 patients. Factor analysis, an item response theory-based model, and an internal consistency test were used to identify attributes and evaluate items. Two(More)
Passively correctable joint deformities of the feet were found in 13 of 14 (82.8%) systemic lupus erythematosus (SLE) patients with deforming arthropathy of the hands (Jaccoud's type of arthropathy). These included hallux valgus, subluxation of the metatarsophalangeal joints and widening of the forefoot. Erosive or cystic changes of bone and cartilage were(More)
OBJECTIVE Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double-blind, placebo-controlled trials, the EMBODY 1 and EMBODY 2 trials, assessing the efficacy and safety of epratuzumab(More)
OBJECTIVE To estimate weights for health states comprising American College of Rheumatology (ACR) response and different levels of adverse events associated with rheumatoid arthritis (RA) treatments. METHODS A survey was mailed to 748 patients with RA from southern California. In addition to several questionnaires commonly used for patients with RA,(More)
Early intervention with drugs that delay structural damage from rheumatoid arthritis may limit disability and reduce the high costs associated with advancing disease. However, conventional agents have a potential for significant toxicities, which require monitoring that confers additional treatment costs. A new class of drugs has been developed: biologic(More)
  • 1